OctoPlus Opens New GMP Manufacturing Facility
OctoPlus has started production in its new manufacturing facility in Leiden.
Netherlands-based biopharmaceutical company OctoPlus N.V. has started pharmaceutical production in its new manufacturing facility in Leiden. The facility has received a license from the Dutch authorities to manufacture pharmaceutical products according to international good manufacturing practice (GMP) guidelines.
OctoPlus began expanding its headquarters in November 2006. The new building comprises offices, laboratories, and a GMP manufacturing plant that produces final drug product for the company’s clients.
With the expansion, OctoPlus has more than doubled its manufacturing capacity and the company can now produce clinical scale Phase 1, 2, and 3 and even small-scale commercial supplies of injectable pharmaceutical products and other complex formulations.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
